Abstract:Background: Previously known as the anti-rejection drug, then famous for its efficacy on many mTOR-regulated diseases, sirolimus is now reported as the drug to reverse the process of many age-related diseases, rejuvenate immunity, and extend life span. However, its long-term safety profile for all-age groups is still a concern.Methods: Data were from two 10-year prospective cohort studies (ChiCTR-OOB-15006535,NCT031938), in which patients were diagnosed with tuberous sclerosis and/or lymphangioleiomyomatosis. Indicators on growth, hematopoietic, liver and renal function, and blood lipid were all primary outcomes. GLM analysis and Chi-square test were used to reveal their changes between the baseline and five follow-up periods (< 6 months, 6 to < 12 months, 1 to < 2 years, 2 to < 4 years, and 4-to-10 years)). Four models with cross-validation were constructed for prediction. Descriptive adverse events and the change of regimens were also recorded (secondary outcomes). Findings: 1738 patients aging from 5 days to 69 years were included. The median follow-up period was 25 (12-43) months, and 380 patients were followed for more than four years. Z scores of height, weight, and BMI increased significantly throughout the follow-up (baseline versus 4-to-10-year follow-up: 0·24 vs 0·69, 0·25 vs 0·56, 0·14 vs 0·29). The dose of sirolimus was the only factor related to all the changes. No negative effects on hematopoietic, liver, and renal function were observed throughout the follow-up. On the contrary, the long-term use of sirolimus showed beneficial effects. The increase of blood lipids was mainly in the first six months. Stomatitis was the most common adverse event (920/1738, 52·9% ), and 48·5% of adult females were with menstrual disorders. The economic burden was the main reason for discontinuing therapy.Interpretation: For the first time, we observed the increase in height and weight brought by sirolimus. Also, the length of follow-up was associated with different safety profiles. Some beneficial effects were observed in a longer follow-up.Clinical Trial Registration Details: The pediatric patients in this study are from the "Efficacy and Safety of Sirolimus in Pediatric Patients with Tuberous Sclerosis (ESOSIPT)" study (Chinese Clinical Trial Registration, http://www.chictr.org.cn, No. ChiCTR-OOB-15006535). The adult patients re from "A National Registry on Chinese Patients with Lymphangioleiomyomatosis" (ClinicalTrials.gov, No. NCT03193892).Funding Information: This work was supported by grants from the National Key Research and Development Program of China (No. 2016YFC1000707,No.2016YFC0901502) and the National Natural Science Foundation of China (No. 81471329).Declaration of Interests: The authors have no conflicts of interest relevant tothis article to disclose.Ethics Approval Statement: The Ethics Committee of Chinese PLA General Hospital approved the pediatric study (No. S2013-028-01). The Ethics Committee of Peking Union Medical College Hospital (PUMCH) approved the adult study(JS-1323).

A prospective multicenter study of sirolimus for complicated vascular anomalies

Sirolimus for vascular anomalies in the first year of life: a systematic review

Therapy with sirolimus in vascular anomalies: the experience of two Italian centers on 14 pediatric patients

Therapeutic Drug Monitoring for Sirolimus in Children with Vascular Anomalies: What Can We Learn from a Retrospective Study

Sirolimus experience in adult patients with vascular malformations

Experience in the Treatment of Lymphatic Vascular Malformations with Sirolimus, A Prospective Cohort Study in a Tertiary Hospital

Three‐year Clinical Outcomes of the Novel Sirolimus‐eluting Bioresorbable Scaffold for the Treatment of De Novo Coronary Artery Disease: A Prospective Patient‐level Pooled Analysis of NeoVas Trials

Sirolimus treatment for intractable lymphatic anomalies: an open-label, single-arm, multicenter, prospective trial

Sirolimus for vascular anomalies associated with PTEN hamartoma tumor syndrome

Cost‐utility of sirolimus in the treatment of vascular malformations

Sirolimus plus prednisolone vs sirolimus monotherapy for kaposiform hemangioendothelioma: a randomized clinical trial

Long‐term effects of sirolimus treatment for slow‐flow vascular malformations: Real‐world evidence from the French observational multicentre SIROLO study

Sirolimus combined with glucocorticoids in the treatment of Kasabach-Merritt phenomenon in a neonate: A case report

Safety Profile of Sirolimus in All Age Groups: A Pooled Analysis of Two 10-Year Cohort Studies Comprising 1738 Patients With Tuberous Sclerosis and/or Lymphangioleiomyomatosis

Long-term safety and influence on growth in patients receiving sirolimus: a pooled analysis

Optimization of Initial Dose Regimen for Sirolimus in Pediatric Patients With Lymphangioma

Exploratory study of autophagy inducer sirolimus for childhood cerebral adrenoleukodystrophy

Sirolimus Can Increase the Disappearance Rate of Cardiac Rhabdomyomas Associated with Tuberous Sclerosis: A Prospective Cohort and Self-Controlled Case Series Study

Efficacy and Safety of Mtor Inhibitors (rapamycin and Its Analogues) for Tuberous Sclerosis Complex: a Meta-Analysis

[Clinical Analysis of Sirolimus As an Alternative GVHD Prophylaxis for Patients with Kidney Injury Undergoing Allo-Hsct].

Conversion from cyclosporine to sirolimus in chronic renal allograft dysfunction: a 4-year prospective study.